Bedinvetmab (Librela/Beransa) in dogs raises safety concerns, including rapidly progressive osteoarthritis, and warrants vigilant adverse event reporting.

Bedinvetmab (Librela/Beransa) is a canine anti-nerve growth factor monoclonal antibody (aNGFmAb) approved for the management of osteoarthritis pain. By neutralizing NGF, it reduces nociceptive signaling and improves comfort. However, NGF plays critical roles in neural, bone, and cartilage homeostasis across species. Multiple studies indicate that NGF contributes to bone remodeling and cartilage repair by modulating osteoblast, osteoclast, and chondrocyte activity, processes that are highly active in osteoarthritic joints. In humans, rodents, and rabbits, inhibition of NGF is associated with rapidly progressive osteoarthritis, a serious adverse event characterized by accelerated joint destruction and collapse, which ultimately prevented regulatory approval of human aNGFmAbs-yet the canine aNGFmAb, bedinvetmab, received marketing authorization. Emerging clinical signals in canine patients raise concern that NGF blockade may similarly mask early structural deterioration, potentially accelerating osteolysis and chondrolysis in both index joints and nonindex joints. Although purportedly rare, those adverse drug events are irreversible and often catastrophic, resulting in rapid joint degeneration, progressive osseous collapse, and fractures, which can occur within months. This stands in contrast to high reported clinician satisfaction rates and underscores the need for careful postmarketing vigilance. Given NGF's integral role in joint biology, objective monitoring strategies are warranted. These strategies should include thorough baseline and follow-up examinations, standardized imaging protocols, diligent adverse event reporting, and, where appropriate, histopathological assessment. Transparent communication of potential risks, along with documented informed consent, is essential to support balanced, clinical decision-making by veterinarians and pet owners.